Phaseline

Targets › COX1

COX1 (Prostaglandin G/H synthase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout May 2027.

Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the…. (UniProt, P23219)

Open in Phaseline: the race on COX1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Avidence TherapeuticsAVD275 Intra-articular Injection
Cyclooxygenase (COX) inhibitor
COX1, COX2Phase 1Osteoarthritis of the KneeMay 2027

Conditions

Osteoarthritis of the Knee (1)

Modalities

small molecule (1)

Companies

Avidence Therapeutics (1)

Related targets

COX2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.